Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03357952
Title A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Age Groups: adult | senior
Covered Countries ESP | BEL

No variant requirements are available.